Abstract

Reactive carbonyl compounds are formed during autoxidation of carbohydrates and peroxidation of lipids. These compounds are intermediates in the formation of advanced glycation end products (AGE) and advanced lipoxidation end products (ALE) in tissue proteins during aging and in chronic disease. We studied the reaction of carbonyl compounds glyoxal (GO) and glycolaldehyde (GLA) with pyridoxamine (PM), a potent post-Amadori inhibitor of AGE formation in vitro and of development of renal and retinal pathology in diabetic animals. PM reacted rapidly with GO and GLA in neutral, aqueous buffer, forming a Schiff base intermediate that cyclized to a hemiaminal adduct by intramolecular reaction with the phenolic hydroxyl group of PM. This bicyclic intermediate dimerized to form a five-ring compound with a central piperazine ring, which was characterized by electrospray ionization-liquid chromatography/mass spectrometry, NMR, and x-ray crystallography. PM also inhibited the modification of lysine residues and loss of enzymatic activity of RNase in the presence of GO and GLA and inhibited formation of the AGE/ALE N(epsilon)-(carboxymethyl)lysine during reaction of GO and GLA with bovine serum albumin. Our data suggest that the AGE/ALE inhibitory activity and the therapeutic effects of PM observed in diabetic animal models depend, at least in part, on its ability to trap reactive carbonyl intermediates in AGE/ALE formation, thereby inhibiting the chemical modification of tissue proteins.

Highlights

  • Reactive carbonyl compounds are formed during autoxidation of carbohydrates and peroxidation of lipids

  • We studied the reaction of carbonyl compounds glyoxal (GO) and glycolaldehyde (GLA) with pyridoxamine (PM), a potent postAmadori inhibitor of advanced glycation end products (AGE) formation in vitro and of development of renal and retinal pathology in diabetic animals

  • Our data suggest that the AGE/advanced lipoxidation end products (ALE) inhibitory activity and the therapeutic effects of PM observed in diabetic animal models depend, at least in part, on its ability to trap reactive carbonyl intermediates in AGE/ALE formation, thereby inhibiting the chemical modification of tissue proteins

Read more

Summary

Mechanism of AGE Inhibition by Pyridoxamine

Ral intermediate of vitamin B6 metabolism, prevented the development of nephropathy in the rat model of diabetes (Baynes and co-authors, Refs. 26 and 27). Our earlier studies of the mechanism of action of PM suggest that it acts by inhibiting the conversion of intermediates in protein glycation reactions (Amadori compounds) to advanced glycation end products, such as CML We extend our studies into the mechanism of action of PM by showing that it inhibits protein modifications by GO and GLA, major products of sugar and lipid degradation. Pyridoxamine exerts this protective effect by competing with protein lysine residues for dicarbonyl and ␣-hydroxycarbonyl moieties of GO and GLA, respectively, to form relatively stable cyclic aminal derivatives, GOPM and GLAPM. We suggest that pyridoxamine acts through this mechanism in addition to its inhibition of postAmadori protein modifications established in our earlier studies (28 –30)

EXPERIMENTAL PROCEDURES
RESULTS
Carbon atoma
DISCUSSION
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call